High priorities: sustainability & continual improvement LEARN MORE>
High priorities: sustainability & continual improvement
Actavis Net Revenue Increases 59% to $2.779 Billion in Fourth Quarter 2013 LEARN MORE>
Actavis Net Revenue Increases 59% to $2.779 Billion in Fourth Quarter 2013
>Go!

Company Profile

Actavis plc (NYSE: ACT) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products.

The Company has global headquarters in Dublin, Ireland and Administrative Headquarters in Parsippany, New Jersey, USA.

Highlights

  • Actavis markets approximately 1000 generic, branded generic, established brands and Over-the-Counter (OTC) pharmaceutical products globally through operations in more than 60 countries.
  • Actavis is committed to developing and marketing biosimilar products in Women’s Health, Oncology and other therapeutic categories.
  • Actavis Global Operations has more than 30 manufacturing and distribution facilities around the world, and includes Anda, Inc., a U.S. pharmaceutical product distributor.
  • Actavis develops and out-licenses generic pharmaceutical products to customers in more than 100 countries outside of the U.S. through its Medis third-party business.